Huperzine A — The Acetylcholinesterase Inhibitor

Huperzine A acts as a highly specific, reversible inhibitor of acetylcholinesterase (AChE), preventing the breakdown of acetylcholine and increasing its synaptic availability. Beyond AChE inhibition, it exhibits neuroprotective effects by reducing reactive oxygen species (ROS) generation and attenuating neuroinflammation. It has been shown to upregulate the cholinergic anti-inflammatory pathway, potentially inhibiting immunosenescence and reducing the transcription of pro-inflammatory cytokines like TNF-α.

Multiple randomized clinical trials have investigated Huperzine A in patients with Alzheimer's disease and vascular dementia, generally reporting significant improvements in cognitive function. However, large-scale human trials specifically evaluating its efficacy as a preventative longevity intervention in healthy populations are currently lacking.

In clinical trials for cognitive decline, doses typically range from 200 to 400 mcg per day, often divided into two doses. For general cognitive support, supplements usually provide 50 to 200 mcg per day. It is often cycled to prevent tolerance, though clinical consensus on cycling is unestablished.

Generally well-tolerated at standard doses, but can cause cholinergic adverse effects including nausea, diarrhea, sweating, and muscle twitching. It is contraindicated in individuals with bradycardia, epilepsy, peptic ulcer disease, or asthma. It should not be combined with other acetylcholinesterase inhibitors or cholinergic drugs.

Key Papers